<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The European Medicines Agency has recommended the European Commission to reject Biogen Inc’s (NASDAQ: BIIB) Aduhelm, an expected blow to its hopes of finding a widespread market for its struggling Alzheimer’s drug. The EMA recommendation had been expected since the EMA’s human medicines committee gave Biogen “a negative trend vote” after an oral presentation from the Company.
...read full article on Benzinga
